Hangzhou Century (SZSE:300078) Adds CN¥480m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 72%
Hangzhou Century (SZSE:300078) Adds CN¥480m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 72%
Hangzhou Century Co., Ltd (SZSE:300078) shareholders will doubtless be very grateful to see the share price up 60% in the last quarter. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 72% in that time. The recent bounce might mean the long decline is over, but we are not confident. The important question is if the business itself justifies a higher share price in the long term.
思创医惠股份有限公司(SZSE:300078)的股东无疑会非常感激,在最后一个季度股票价格上涨了60%。但是,这能否弥补过去5年下降带来的所有创伤呢?不太可能。事实上,在这段时间内,股价暴跌了72%。最近的反弹可能意味着长期的下跌已经结束,但我们并不自信。关键问题是,这个业务本身是否在长期内能证明其股票价格更高的价值。
The recent uptick of 14% could be a positive sign of things to come, so let's take a look at historical fundamentals.
最近14%的反弹可能是有望好转的积极迹象,因此让我们看一下历史基本面。
Hangzhou Century isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
思创医惠目前并未盈利,因此大多数分析师会关注营业收入的增长,以了解基础业务的增长速度。无盈利公司的股东通常渴望强劲的营业收入增长。这是因为,如果营业收入增长微不足道且从未盈利,就很难对公司的可持续性感到信心。
In the last five years Hangzhou Century saw its revenue shrink by 14% per year. That's definitely a weaker result than most pre-profit companies report. So it's not altogether surprising to see the share price down 11% per year in the same time period. This kind of price performance makes us very wary, especially when combined with falling revenue. Ironically, that behavior could create an opportunity for the contrarian investor - but only if there are good reasons to predict a brighter future.
在过去五年中,思创医惠的营业收入每年萎缩14%。这绝对是一个比大多数未盈利公司报告的结果要弱的。因此,在同一时期内看到股价每年下降11%也就不足为奇了。这种价格表现让我们非常警惕,尤其是在营业收入下滑的情况下。具有讽刺意味的是,这种行为可能为逆势投资者创造机会——但前提是有充分的理由预测更光明的未来。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
你可以在这个免费的互动图表中看到它的资产负债表如何随着时间的推移而加强(或削弱)。
A Different Perspective
另一种看法
Hangzhou Century shareholders are down 21% for the year, but the market itself is up 4.9%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 11% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. It's always interesting to track share price performance over the longer term. But to understand Hangzhou Century better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Hangzhou Century you should be aware of, and 1 of them is a bit unpleasant.
思创医惠的股东今年下跌了21%,但市场本身上涨了4.9%。即使是好股票的股价有时也会下跌,但在我们过于关注之前,我们希望看到业务的基本指标有所改善。然而,过去一年的损失并不像过去五年投资者每年11%的损失那么严重。我们希望有明确的信息表明公司将会增长,然后再考虑股价会稳定的观点。长期跟踪股价表现总是很有趣的。但为了更好地了解思创医惠,我们需要考虑许多其他因素。一个例子:我们发现思创医惠有3个你应该知道的警告信号,其中1个有点不太愉快。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果您和我一样,那么您一定不想错过这份免费的被内部人员买入的低估小盘股清单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文中引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。